WO1994007503A1 - Enteric preparations - Google Patents

Enteric preparations Download PDF

Info

Publication number
WO1994007503A1
WO1994007503A1 PCT/FI1993/000389 FI9300389W WO9407503A1 WO 1994007503 A1 WO1994007503 A1 WO 1994007503A1 FI 9300389 W FI9300389 W FI 9300389W WO 9407503 A1 WO9407503 A1 WO 9407503A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
enteric
sucralfate
treatment
intestine
Prior art date
Application number
PCT/FI1993/000389
Other languages
French (fr)
Inventor
Kaija Kristiina Af Ursin
Markku Juho Ylermi ÄÄRIMAA
Harry Gösta JALONEN
Original Assignee
Orion-Yhtymä Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion-Yhtymä Oy filed Critical Orion-Yhtymä Oy
Priority to AU48215/93A priority Critical patent/AU4821593A/en
Publication of WO1994007503A1 publication Critical patent/WO1994007503A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • This invention relates to enteric pharmaceutical preparations containing disaccharide polysulfate complexes, especially sucralfate, useful in the treatment of intestinal disorders.
  • the intestinal disorders may be ulceration and/or inflammation in the intestine, particularly in the small intestine and colon, especially Crohn's disease and ulcerative colitis, and injury caused by radiotherapy or cytotoxic drugs.
  • this invention relates to the use of disaccharide polysulfate complexes, especially sucralfate, in the preparation of enteric pharmaceutical preparations useful in the treatment of intestinal disorders, especially ulceration and/or inflammation in the intestine, particularly in the small intestine and colon, more particularly Crohn's disease and ulcerative colitis, or injury caused by radiotherapy or cytotoxic drugs.
  • Sucralfate a disaccharide polysulfate aluminium compound and more specifically alpha-D-glucopyranoside, beta-fructofuranosyl-, octakis (hydrogen sulfate), aluminium complex
  • a basic aluminium sucrose sulphate complex which accelerates the healing of gastric and duodenal ulcers.
  • the preparations on the market release sucralfate already in the stomach where it forms a gel-like mass interacting the mucous membrane in the stomach and is shown to have a healing effect on ulcers.
  • the intestine is not targetted for treatment.
  • Sucralfate may be replaced by other disaccharide polysulfate complexes other than those of aluminium, for example an alkaline earth metal (e.g. Ca, K or Mg) or Bi.
  • an alkaline earth metal e.g. Ca, K or Mg
  • Bi e.g. Bi, Bi.
  • enteral means a medicinal preparation formulated to pass through the stomach unaltered and disintegrate in the intestine. No effective cure has been found for the group of patients suffering from ulceration and/or inflammation in the intestine, especially in the distal small intestine and colon, or injury caused by radiotherapy or cytotoxic drugs.
  • the sucralfate preparations in the market are not suitable for the treatment of for example ileitis, Crohn's disease, ulcerative colitis and related colo-rectal lesions.
  • the present invention provides enteric disaccharide polysulfate complex, particularly sucralfate, preparations suitable for the treatment of intestinal disorders, especially ulceration and/or inflammation in the intestine, especially in the distal small intestine and colon, and injury caused by radiotherapy or cytotoxic drugs.
  • enteric disaccharide polysulfate complex especially sucralfate, preparations for the treatment of Crohn's disease and ulcerative colitis.
  • the dissolution of the suitable enteric coating materials is dependent on pH.
  • the enteric coating material may be any material which inhibits disaccharide polysulfate complexes to be released in the stomach and disintegrate in the intestine or part of the intestine without altering their therapeutic effect.
  • Enteric coating materials which may be used in preparations targetted for the treatment of the small intestine should be insoluble in gastric juice and be soluble in intestinal juice below pH 7.
  • Enteric coating materials which may be used in preparations targetted for the treatment of the colon should be insoluble in gastric juice and intestinal juice below about pH 7 and be soluble in intestinal juice above about pH 7.
  • the enteric coating material may also be a combination of two or more materials when it is desired to target preparations for a particular part of the intestine or for the treatment of both the small intestine and the colon. According to the invention it may be possible to treat the whole intestine with a single enteric preparation or only the part of the intestine desired.
  • the amount of the active ingredient, i.e. the disaccharide polysulfate complex, especially sucralfate, in the enteric preparations should be sufficient to achieve a therapeutic effect in the intestine.
  • the amount of sucralfate administered may be up to about 4 g day which may be divided into two or more dosages if desired.
  • the enteric coating materials may be natural polymers, such as hydroxypropyl methylcellulose or its derivatives, such as hydroxypropyl methylcellulose phthalate or polyvinyl acetate phthalate, or synthetic polymers, preferably (meth)acrylic acid and (meth)acrylic acid ester copolymers, such as EUDRAGIT polymers or their derivatives.
  • EUDRAGIT L which disintegrates in the pH value of below 7 may be used for preparations designed to treat the small intestine and EUDRAGIT S which disintegrates in the pH value above 7 for preparations designed to treat the colon.
  • the forms of administering the enteric disaccharide polysulfate complex, especially sucralfate may include tablets, solid dispersions, granules, pellets, capsules, mixtures and any other dosage form which may be suitable for oral administration.
  • the preparations may be made by conventional methods and coating techniques.
  • Tablets may be coated with an enteric coating material or they may be prepared using enteric coated granules or pellets.
  • Enteric coated granules and pellets may also be used as such as a bulk material, packed into capsules suitable for oral administration and which dissolve in the stomage, e.g. gelatin capsules, or formed into multiple unit tablets by mixing with a disintegrant, such as Explotab, and when desired also other fillers, such as microcrystalline cellulose and tabletting in a suitable tabletting machine.
  • a disintegrant such as Explotab
  • Capsules and multiple unit tablets may still be coated with an enteric coating material if desired.
  • the disaccharide polysulfate complex granules or pellets may be mixed with an enteric coating material.
  • the granulation may be performed by conventional methods, such as in a fluidized bed or high-shear granulator.
  • Pellets may be produced by conventional methods, such as with extrusion/spheronization technique.
  • the pellets suitable for the preparations of the invention are about 0.5-1.5 mm diameter, especially about 1 mm diameter.
  • the active ingredient may also be granulated or pelleted using a solution or dispersion of an enteric coating material as a binder.
  • the enteric coating material acts as a matrix.
  • Enteric coated raw material particles or small agglomerates may be used in the preparation of dosage forms described above. Especially they are useful in preparing mixtures. They may also be used as a bulk material.
  • the enteric preparation may also be made of granules and/or pellets coated with different enteric coating materials to achieve a multicomponent preparation which releases the active ingredient according to pH gradient in the intestine.
  • a layer of a retarding agent such as hydroxypropyl methylcellulose, methyl hydroxy- ethylcellulose, ethylcellulose, hydroxypropylcellulose, polyvidone, sodium carboxymethylcellulose, polyethylene glycols and acrylate polymers.
  • enteric preparations of the invention may contain suitable pharmaceutically acceptable additives, such as fillers, binders, disintegrants, lubricants, plasticizers, solvents, etc..
  • the amount of enteric coating material required in the enteric preparations will depend on the dissolution properties of the particular enteric coating material and the planned dosage form in mind. Usually the amount of enteric coating material will be up to 25 % (dry weight gain).
  • the enteric coating may be applied from solvent based solutions or aqueous dispersions. Suitable solvents are for example different alcohols, such as iso-propanol and ethanol, and acetone or their mixtures.
  • the solvent based solutions may also contain water, usually at most one equivalent, and the aqueous dispersions may contain water misciple organic solvents.
  • the enteric coating may contain additives, such as colouring agents, plasticizers, such as alkylphthalates (e.g. dibutylphthalate), polyethylene glycol, triacetin, citric acid esters and propylene glycol, auxiliary materials, e.g. talc, etc..
  • the coating to the preparations may be achieved by conventional coating techniques as defined above, such as by the use of spraying, fluidized bed, immersion tube and immersion bed techniques.
  • ANTEPSIN® tablets which consist of 1 g of sucralfate are coated by a conventional spraying technique with a solution of 50 g of EUDRAGIT S100, 14 g of dibutylphtalat, 500 g of acetone and 500 g of iso-propanol. After the coating the tablets are allowed to dry.
  • the amount of EUDRAGIT SI 00 per tablet is 42,2 mg.
  • the coated sucralfate tablets resist 0,1 M HC1 solution, which resembles the conditions in the stomach. All the tested tablets disintegrated in pH 7,2 in about 9 to 53 minutes.
  • Sucralfate is granulated in fluidized bed granulator using Kollidon 30 solution (20 %) as a binder.
  • the amount of Kollidon in final dry granules is 8 %.
  • Dry sucralfate granules are coated using aqueous dispersion of EUDRAGIT L 30 D.
  • the composition of the coating dispersion is as follows:
  • 60 g of coating liquid is needed for 100 g of granules.
  • Multiple unit tablets are prepared by mixing enteric coated granules (90 %) prepared in Example 2 with a disintegrant EXPLOTAB (10 %). The mixture is tabletted with a single punch tabletting machine to give multiple unit tablets weighing 0,5 grams.
  • Sucralfate is granulated in fluidized bed granulator using EUDRAGIT L 30 D water dispersion as a binder.
  • the amount of dry substances of binder dispersion in final granules is 13 %.
  • Sucralfate (80 %) and microcrystalline cellulose (20 %) are granulated with distilled water (80 % of dry substances) for further production of extrudate and pellets with extrusion/spheronization technique.
  • the pellets are dried and coated with enteric coating in fluidized bed equipment.
  • the composition of coating solution is the same as in Example 2 and 4.
  • the amount of dry substances of the coating dispersion in final pellets is 10 %.
  • Sucralfate particles are coated with EUDRAGIT L 30 D water dispersion as described in Example 2. Coated particles are used for the preparation of a mixture as follows:

Abstract

Enteric pharmaceutical preparations containing a disaccharide polysulfate complex, especially sucralfate, suitable for use in the treatment of intestinal disorders, which may be ulceration and/or inflammation in the intestine, especially in the distal small intestine and colon, and injury caused by radiotherapy or cytotoxic drugs.

Description

ENTERIC PREPARATIONS
This invention relates to enteric pharmaceutical preparations containing disaccharide polysulfate complexes, especially sucralfate, useful in the treatment of intestinal disorders. The intestinal disorders may be ulceration and/or inflammation in the intestine, particularly in the small intestine and colon, especially Crohn's disease and ulcerative colitis, and injury caused by radiotherapy or cytotoxic drugs.
Further this invention relates to the use of disaccharide polysulfate complexes, especially sucralfate, in the preparation of enteric pharmaceutical preparations useful in the treatment of intestinal disorders, especially ulceration and/or inflammation in the intestine, particularly in the small intestine and colon, more particularly Crohn's disease and ulcerative colitis, or injury caused by radiotherapy or cytotoxic drugs.
Sucralfate, a disaccharide polysulfate aluminium compound and more specifically alpha-D-glucopyranoside, beta-fructofuranosyl-, octakis (hydrogen sulfate), aluminium complex, is well known in the art as a basic aluminium sucrose sulphate complex which accelerates the healing of gastric and duodenal ulcers. The preparations on the market release sucralfate already in the stomach where it forms a gel-like mass interacting the mucous membrane in the stomach and is shown to have a healing effect on ulcers. The intestine is not targetted for treatment.
Sucralfate may be replaced by other disaccharide polysulfate complexes other than those of aluminium, for example an alkaline earth metal ( e.g. Ca, K or Mg) or Bi.
The term "enteric" means a medicinal preparation formulated to pass through the stomach unaltered and disintegrate in the intestine. No effective cure has been found for the group of patients suffering from ulceration and/or inflammation in the intestine, especially in the distal small intestine and colon, or injury caused by radiotherapy or cytotoxic drugs. The sucralfate preparations in the market are not suitable for the treatment of for example ileitis, Crohn's disease, ulcerative colitis and related colo-rectal lesions.
International specification WO 91/04034 proposes the use of topical sucralfate preparations for treatment of e.g. ulcerative colitis. The specification does not suggest enteric sucralfate preparations to treat the colon but a retention enema was proposed.
The present invention provides enteric disaccharide polysulfate complex, particularly sucralfate, preparations suitable for the treatment of intestinal disorders, especially ulceration and/or inflammation in the intestine, especially in the distal small intestine and colon, and injury caused by radiotherapy or cytotoxic drugs. In particular the present invention provides enteric disaccharide polysulfate complex, especially sucralfate, preparations for the treatment of Crohn's disease and ulcerative colitis.
The dissolution of the suitable enteric coating materials is dependent on pH.
The enteric coating material may be any material which inhibits disaccharide polysulfate complexes to be released in the stomach and disintegrate in the intestine or part of the intestine without altering their therapeutic effect. Enteric coating materials which may be used in preparations targetted for the treatment of the small intestine should be insoluble in gastric juice and be soluble in intestinal juice below pH 7. Enteric coating materials which may be used in preparations targetted for the treatment of the colon should be insoluble in gastric juice and intestinal juice below about pH 7 and be soluble in intestinal juice above about pH 7. The enteric coating material may also be a combination of two or more materials when it is desired to target preparations for a particular part of the intestine or for the treatment of both the small intestine and the colon. According to the invention it may be possible to treat the whole intestine with a single enteric preparation or only the part of the intestine desired.
The amount of the active ingredient, i.e. the disaccharide polysulfate complex, especially sucralfate, in the enteric preparations should be sufficient to achieve a therapeutic effect in the intestine. Generally for example the amount of sucralfate administered may be up to about 4 g day which may be divided into two or more dosages if desired.
The enteric coating materials may be natural polymers, such as hydroxypropyl methylcellulose or its derivatives, such as hydroxypropyl methylcellulose phthalate or polyvinyl acetate phthalate, or synthetic polymers, preferably (meth)acrylic acid and (meth)acrylic acid ester copolymers, such as EUDRAGIT polymers or their derivatives. Especially EUDRAGIT L which disintegrates in the pH value of below 7 may be used for preparations designed to treat the small intestine and EUDRAGIT S which disintegrates in the pH value above 7 for preparations designed to treat the colon.
The forms of administering the enteric disaccharide polysulfate complex, especially sucralfate, may include tablets, solid dispersions, granules, pellets, capsules, mixtures and any other dosage form which may be suitable for oral administration. The preparations may be made by conventional methods and coating techniques.
Tablets may be coated with an enteric coating material or they may be prepared using enteric coated granules or pellets. Enteric coated granules and pellets may also be used as such as a bulk material, packed into capsules suitable for oral administration and which dissolve in the stomage, e.g. gelatin capsules, or formed into multiple unit tablets by mixing with a disintegrant, such as Explotab, and when desired also other fillers, such as microcrystalline cellulose and tabletting in a suitable tabletting machine. Capsules and multiple unit tablets may still be coated with an enteric coating material if desired. In the case of solid dispersions or mixtures the disaccharide polysulfate complex granules or pellets may be mixed with an enteric coating material. The granulation may be performed by conventional methods, such as in a fluidized bed or high-shear granulator. Pellets may be produced by conventional methods, such as with extrusion/spheronization technique. Usually the pellets suitable for the preparations of the invention are about 0.5-1.5 mm diameter, especially about 1 mm diameter.
The active ingredient may also be granulated or pelleted using a solution or dispersion of an enteric coating material as a binder. In this case the enteric coating material acts as a matrix.
Enteric coated raw material particles or small agglomerates may be used in the preparation of dosage forms described above. Especially they are useful in preparing mixtures. They may also be used as a bulk material.
The enteric preparation may also be made of granules and/or pellets coated with different enteric coating materials to achieve a multicomponent preparation which releases the active ingredient according to pH gradient in the intestine.
It may also be possible to coat tablets, granules, pellets and particles/agglomerates with two or more successive layers of different enteric coating materials. One or more of the above layers may be replaced by a layer of a retarding agent, such as hydroxypropyl methylcellulose, methyl hydroxy- ethylcellulose, ethylcellulose, hydroxypropylcellulose, polyvidone, sodium carboxymethylcellulose, polyethylene glycols and acrylate polymers.
The enteric preparations of the invention may contain suitable pharmaceutically acceptable additives, such as fillers, binders, disintegrants, lubricants, plasticizers, solvents, etc..
The amount of enteric coating material required in the enteric preparations will depend on the dissolution properties of the particular enteric coating material and the planned dosage form in mind. Usually the amount of enteric coating material will be up to 25 % (dry weight gain). The enteric coating may be applied from solvent based solutions or aqueous dispersions. Suitable solvents are for example different alcohols, such as iso-propanol and ethanol, and acetone or their mixtures. The solvent based solutions may also contain water, usually at most one equivalent, and the aqueous dispersions may contain water misciple organic solvents. The enteric coating may contain additives, such as colouring agents, plasticizers, such as alkylphthalates (e.g. dibutylphthalate), polyethylene glycol, triacetin, citric acid esters and propylene glycol, auxiliary materials, e.g. talc, etc..
The coating to the preparations may be achieved by conventional coating techniques as defined above, such as by the use of spraying, fluidized bed, immersion tube and immersion bed techniques.
The following non-limiting examples illustrate the invention. The enteric preparations illustrated in the examples meet the requirements of the United States Pharmacopeia (USP) disintegration test for enteric coated tablets.
EXAMPLE 1
Tablet
Commercial ANTEPSIN® tablets which consist of 1 g of sucralfate are coated by a conventional spraying technique with a solution of 50 g of EUDRAGIT S100, 14 g of dibutylphtalat, 500 g of acetone and 500 g of iso-propanol. After the coating the tablets are allowed to dry. The amount of EUDRAGIT SI 00 per tablet is 42,2 mg.
The coated sucralfate tablets resist 0,1 M HC1 solution, which resembles the conditions in the stomach. All the tested tablets disintegrated in pH 7,2 in about 9 to 53 minutes.
The disintegration of the coated ANTEPSIN® tablets was tested in vitro in ERWEKA ZT3 dissolution apparatus in phosphate buffer pH 7,2 in 37 °C according to European Pharmacopoeia 2nd edition. These conditions resemble the conditions in colon. EXAMPLE 2
Granule
Sucralfate is granulated in fluidized bed granulator using Kollidon 30 solution (20 %) as a binder. The amount of Kollidon in final dry granules is 8 %. Dry sucralfate granules are coated using aqueous dispersion of EUDRAGIT L 30 D. The composition of the coating dispersion is as follows:
Figure imgf000008_0001
60 g of coating liquid is needed for 100 g of granules.
EXAMPLE 3
Multiple unit tablet
Multiple unit tablets are prepared by mixing enteric coated granules (90 %) prepared in Example 2 with a disintegrant EXPLOTAB (10 %). The mixture is tabletted with a single punch tabletting machine to give multiple unit tablets weighing 0,5 grams.
EXAMPLE 4
Granule with an enteric coating material as a matrix
Sucralfate is granulated in fluidized bed granulator using EUDRAGIT L 30 D water dispersion as a binder. The binder dispersion composed of EUDRAGIT L 30 D (50 %), triacetin (1,5 %) and water (48,5 %). The amount of dry substances of binder dispersion in final granules is 13 %. EXAMPLE 5
Pellet
Sucralfate (80 %) and microcrystalline cellulose (20 %) are granulated with distilled water (80 % of dry substances) for further production of extrudate and pellets with extrusion/spheronization technique. The pellets are dried and coated with enteric coating in fluidized bed equipment. The composition of coating solution is the same as in Example 2 and 4. The amount of dry substances of the coating dispersion in final pellets is 10 %.
EXAMPLE 6
Mixture
Sucralfate particles are coated with EUDRAGIT L 30 D water dispersion as described in Example 2. Coated particles are used for the preparation of a mixture as follows:
coated sucralfate particles 19 % water 63 % glycerol (85 %) 17,5 % xanthan gum 0,5 %

Claims

1. Pharmaceutical preparation suitable for use in the treatment of intestinal disorders which comprises a disaccharide polysulfate complex in combination with an enteric coating material.
2. Pharmaceutical preparation according to claim 1 wherein the disaccharide polysulfate complex is sucralfate.
3. Pharmaceutical preparation according to claims 1 and 2 wherein the enteric coating material includes a synthetic polymer.
4. Pharmaceutical preparation according to claim 3 wherein the synthetic polymer is a copolymer of (meth)acrylic acid and (meth)acrylic acid ester.
5. Pharmaceutical preparation according to claim 4 wherein the synthetic polymer is EUDRAGIT S.
6. Pharmaceutical preparation according to claim 4 wherein the synthetic polymer is EUDRAGIT L.
7. Pharmaceutical preparation according to claims 1 and 2 wherein the enteric coating material includes a natural polymer.
8. Pharmaceutical preparation according to claims 1 to 7 wherein the preparation is in the form of a tablet
9. Pharmaceutical preparation according to claims 1 to 7 wherein the preparation is in the form of a capsule.
10. Pharmaceutical preparation according to claims 1 to 7 wherein the preparation is in the form of a multicomponent preparation.
11. Use of a disaccharide polysulfate complex for the preparation of an enteric pharmaceutical preparation suitable for use in the treatment of intestinal disorders.
12. Use of a disaccharide polysulfate complex according to claim 11 wherein the pharmaceutical preparation is used in the treatment of ulceration and/or inflammation in the intestine.
13. Use of a disaccharide polysulfate complex according to claim 12 wherein the pharmaceutical preparation is used in the treatment of ulceration and/or inflammation in the colon.
14. Use of a disaccharide polysulfate complex according to claim 12 wherein the pharmaceutical preparation is used in the treatment of ulceration and/or inflammation in the small intestine.
15. Use according to claims 11 to 14 wherein the disaccharide polysulfate complex is sucralfate.
PCT/FI1993/000389 1992-10-05 1993-09-29 Enteric preparations WO1994007503A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48215/93A AU4821593A (en) 1992-10-05 1993-09-29 Enteric preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI924470A FI924470A0 (en) 1992-10-05 1992-10-05 SUKRALFATPREPARAT
FI924470 1992-10-05

Publications (1)

Publication Number Publication Date
WO1994007503A1 true WO1994007503A1 (en) 1994-04-14

Family

ID=8535973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1993/000389 WO1994007503A1 (en) 1992-10-05 1993-09-29 Enteric preparations

Country Status (3)

Country Link
AU (1) AU4821593A (en)
FI (1) FI924470A0 (en)
WO (1) WO1994007503A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432489A (en) * 1965-11-05 1969-03-11 Chugai Pharmaceutical Co Ltd Disaccharide polysulfate aluminium compound and method
EP0245855A2 (en) * 1986-05-16 1987-11-19 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparations for application on esophagus mucosa
WO1991004034A1 (en) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Topical preparation for treatment of aphthous ulcers and other lesions
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
JPH05238938A (en) * 1992-02-28 1993-09-17 Teikoku Seiyaku Co Ltd Sucralfate suspension agent and method for administering sucralfate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432489A (en) * 1965-11-05 1969-03-11 Chugai Pharmaceutical Co Ltd Disaccharide polysulfate aluminium compound and method
EP0245855A2 (en) * 1986-05-16 1987-11-19 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparations for application on esophagus mucosa
WO1991004034A1 (en) * 1989-09-15 1991-04-04 Pehrom Pharmaceutical Corporation Topical preparation for treatment of aphthous ulcers and other lesions
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
JPH05238938A (en) * 1992-02-28 1993-09-17 Teikoku Seiyaku Co Ltd Sucralfate suspension agent and method for administering sucralfate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIALOG INFORMATION SERVICES, File 351: Derwent World Patents Index-Latest 1981, Dialog Accession No. 009637808/5, WPI Accession No. 93-331357/42, ('TEIK-' TEIKOKU SEIYAKU KK), "Suspension of Sucralfate - Contains Natural Gum and De-Flocculants"; & JP,A,5 238 938, 17-09-93, 9342. *
DIALOG INFORMATION SERVICES, File Medline, STN Accession No. 91278527, VALLS A. et al.: "Efficacy of Sucralfate in the Prophylaxis of Diarrhea Secondary to Acute Radiation-Induced Enteritis. Preliminary Results of a Double-Blind Randomized Triala", Med Clin (Barch), (30 Mar 1991), 96 (12), 449-52. *

Also Published As

Publication number Publication date
AU4821593A (en) 1994-04-26
FI924470A0 (en) 1992-10-05

Similar Documents

Publication Publication Date Title
CN1119993C (en) Amino-phenol acetate, pseudoephedrine, chlorpheniramine maleate and with and without dextromethorphan rotary granulating and coating
KR100220322B1 (en) Delayed release oral dosage forms for treatment of intestinal disorders
ES2221188T3 (en) PHARMACEUTICAL COMPRESSED CONTAINING DIDANOSINE WITH ENTERIC COATING.
US5631022A (en) Picosulfate dosage form
US5670158A (en) Bisacodyl dosage form
US5277916A (en) Tetracycline dosage form
AU7256091A (en) Taste masking of ibuprofen by fluid bed coating
JP2001505897A (en) Galenic compositions containing opioid antagonists
US5514663A (en) Senna dosage form
WO1998026767A2 (en) Site-specific controlled release dosage formulation for mesalamine
JPH0157090B2 (en)
EP1315481A1 (en) Medicament for treating intestinal diseases
JP2004512298A (en) Delayed and sustained release formulations and methods of using them
CN102526049A (en) Compound diclofenac sodium slow-release preparation and preparation method thereof
SK44299A3 (en) Colonic delivery of weak acid drugs
WO1994007503A1 (en) Enteric preparations
AU627335B2 (en) Aspirin granules with gastroprotectant coating
KR101016832B1 (en) Combination formulation containing mastic for treatment of gastrointestinal ulcer
WO2004087113A1 (en) Pharmaceutical compositions for colon specific delivery
JPS61221116A (en) Tablet composition
KR20090128918A (en) Preparation of sustained release medication containing alfuzosin hcl
MX2008008167A (en) Bursting pellets

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BY CA CZ FI HU JP KR KZ LV NO NZ PL RO RU SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA